Patents by Inventor William R. Ewing

William R. Ewing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS
    Publication number: 20230242569
    Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
    Type: Application
    Filed: February 10, 2023
    Publication date: August 3, 2023
    Inventors: Michael Anthony SCHMIDT, Bin ZHENG, Kyle KNOUSE, Justine deGRUYTER, Martin D. EASTGATE, Phil BARAN, William R. EWING, Richard E. OLSON, Ivar M. MCDONALD
  • Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds
    Patent number: 11613554
    Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: March 28, 2023
    Assignees: Bristol-Myers Squibb Company, The Scripps Research Institute
    Inventors: Michael Anthony Schmidt, Bin Zheng, Kyle Knouse, Justine deGruyter, Martin D. Eastgate, Phil Baran, William R. Ewing, Richard E. Olson, Ivar M. McDonald
  • ANTIBODIES AND ANTIGEN BINDING PEPTIDES FOR FACTOR XIA INHIBITORS AND USES THEREOF
    Publication number: 20220220220
    Abstract: The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.
    Type: Application
    Filed: January 7, 2022
    Publication date: July 14, 2022
    Inventors: Joseph M. Luettgen, Lumelle Schneeweis, Ginger Chao Rakestraw, Christina Terragni, Andrew Karl Dilger, Jason Robert Pinckney, Steven Sheriff, Kevin Kish, Yongmi An, William R. Ewing, Stanley Richard Krystek, JR., Aaron Paul Yamniuk
  • PYRIMIDINONES AS FACTOR XIA INHIBITORS
    Publication number: 20220041601
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: June 15, 2021
    Publication date: February 10, 2022
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • Diazaspiro ROCK inhibitors
    Patent number: 11192891
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: December 7, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yeheng Zhu, Sunita V. Dewnani, William R. Ewing
  • Method of administering nitroxyl donating compounds
    Patent number: 11083704
    Abstract: The disclosed subject matter provides methods of using nitroxyl donating compounds and pharmaceutical compositions comprising such compounds in a dose escalation regimen.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: August 10, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Paul D. Kessler, William R. Ewing, Maria Borentain, Tushar Garimella, Elyse G. Stock
  • Pyrimidinones as factor XIA inhibitors
    Patent number: 11053247
    Abstract: The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: July 6, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J. P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • DIAZASPIRO ROCK INHIBITORS
    Publication number: 20210188848
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: November 1, 2018
    Publication date: June 24, 2021
    Inventors: Yeheng Zhu, Sunita V. Dewnani, William R. Ewing
  • Diamide macrocycles having factor XIa inhibiting activity
    Patent number: 10752641
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: August 25, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jun Shi, William R. Ewing, Donald J. P. Pinto
  • Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group
    Patent number: 10676477
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: June 9, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yeheng Zhu, Andrew K. Dilger, William R. Ewing, Michael J. Orwat, Donald J. P. Pinto
  • PYRIMIDINONES AS FACTOR XIA INHIBITORS
    Publication number: 20200055854
    Abstract: The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: June 25, 2019
    Publication date: February 20, 2020
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • NOVEL SUBSTITUTED GLYCINE DERIVED FXIA INHIBITORS
    Publication number: 20190382378
    Abstract: The present invention provides compounds of Formula (I): (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: June 27, 2019
    Publication date: December 19, 2019
    Inventors: James R. Corte, William R. Ewing, Donald J.P. Pinto, Leon M. Smith, II
  • METHOD OF ADMINISTERING NITROXYL DONATING COMPOUNDS
    Publication number: 20190343790
    Abstract: The disclosed subject matter provides methods of using nitroxyl donating compounds and pharmaceutical compositions comprising such compounds in a dose escalation regimen.
    Type: Application
    Filed: January 2, 2018
    Publication date: November 14, 2019
    Inventors: Paul D. Kessler, William R. Ewing, Maria Borentain, Tushar Garimella, Elyse G. Stock
  • NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS
    Publication number: 20190322694
    Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 24, 2019
    Inventors: Michael Anthony SCHMIDT, Bin ZHENG, Kyle KNOUSE, Justine deGRUYTER, Martin D. EASTGATE, Phil BARAN, William R. EWING, Richard E. OLSON, Ivar M. McDONALD
  • Substituted glycine derived FXIA inhibitors
    Patent number: 10336730
    Abstract: The present invention provides compounds of Formula (I): (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: July 2, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, William R. Ewing, Donald J. P. Pinto, Leon M. Smith, II
  • Pyrimidinones as factor XIa inhibitors
    Patent number: 10336754
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: July 2, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J. P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • FACTOR XIA MACROCYCLES WITH NOVEL P1 GROUPS
    Publication number: 20190144393
    Abstract: The present invention provides compounds of Formula (I): P-Ma??(I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: January 11, 2019
    Publication date: May 16, 2019
    Inventors: James R. Corte, Andrew K. Dilger, William R. Ewing, Donald J.P. Pinto, Wu Yang
  • Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties
    Patent number: 10287288
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: May 14, 2019
    Assignee: Bristol-Myers Squibb
    Inventors: Kumar Balashanmuga Pabbisetty, James R. Corte, Andrew K. Dilger, William R. Ewing, Yeheng Zhu
  • Macrocyclic factor XIa inhibitors bearing heterocyclic groups
    Patent number: 10273236
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: April 30, 2019
    Assignee: Bristol-Myers Squibb
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J. P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • DIAMIDE MACROCYCLES HAVING FACTOR XIA INHIBITING ACTIVITY
    Publication number: 20190062343
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: March 1, 2017
    Publication date: February 28, 2019
    Inventors: Jun Shi, William R. EWING, Donald J.P. PINTO